Drug Trial Radar · NCT04534725
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Dec 17, 2020
Primary completion
Nov 28, 2022
Study completion Apr 19, 2023
Sponsor
- Lead sponsor
- Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population. ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts. ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus. ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection. ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection. Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection. It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.
Conditions
- Cancer
- Covid19
- Respiratory Viral Infection
Interventions
Interferon alfaDrug
intranasal spray
SelinexorDrug
oral tablet
LenzilumabDrug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)Time frame: 3 months from baseline.
- incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testingTime frame: 3 months from baseline.
- incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .Time frame: 28 days from baseline
- incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testingTime frame: 28 days from baseline
- incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical recordsTime frame: 60 days from baseline
- time to clinical improvement or discharge from hospital assessed using medical recordsTime frame: 28 days from baseline
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Westmead Hospital
Westmead, New South Wales, Australia
St Vincent's Hospital
Fitzroy, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Austin Health
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.